Recursion Pharma's Revenue Soars, But Net Losses Widen to $105.3M
Ticker: RXRX · Form: 10-Q · Filed: Aug 5, 2025 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 10-Q |
| Filed Date | Aug 5, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: Biotechnology, Drug Discovery, AI in Pharma, Clinical Stage, Net Loss, Revenue Growth, SEC Filing
Related Tickers: RXRX
TL;DR
Recursion's revenue nearly doubled, but its net loss ballooned to over $100 million, making it a high-risk bet on future drug development.
AI Summary
RECURSION PHARMACEUTICALS, INC. reported total revenue of $10.1 million for the three months ended June 30, 2025, a significant increase from $5.2 million for the same period in 2024, representing a 94.2% year-over-year growth. For the six months ended June 30, 2025, total revenue reached $19.5 million, up from $10.3 million in 2024, an 89.3% increase. The company's net loss for the three months ended June 30, 2025, was $105.3 million, compared to a net loss of $98.7 million in the prior year, indicating a widening loss despite revenue growth. The six-month net loss also increased to $208.1 million in 2025 from $192.5 million in 2024. Key business changes include continued investment in research and development, which is reflected in the increased net loss. Risks primarily revolve around the substantial and growing net losses, indicating high cash burn for a clinical-stage biotech. The strategic outlook focuses on advancing its drug discovery platform, with revenue growth driven by license and service agreements, suggesting ongoing collaborations are crucial for funding operations.
Why It Matters
This filing reveals Recursion Pharmaceuticals' ability to significantly grow revenue from collaborations, up 94.2% year-over-year to $10.1 million, which is critical for a pre-commercial biotech. However, the widening net loss to $105.3 million for the quarter signals continued high cash burn, a key concern for investors evaluating long-term viability and potential dilution. For employees, this growth in revenue could indicate stability and continued investment in R&D, while customers (partners) benefit from the company's advancing platform. In the competitive landscape, Recursion's ability to secure and expand license and service agreements demonstrates its platform's value, but sustained losses could pressure its competitive edge against better-capitalized rivals.
Risk Assessment
Risk Level: high — The company reported a net loss of $105.3 million for the three months ended June 30, 2025, an increase from $98.7 million in the prior year, and a six-month net loss of $208.1 million, up from $192.5 million. These substantial and increasing losses, despite revenue growth, indicate a high cash burn rate and significant reliance on future financing or successful drug development to achieve profitability.
Analyst Insight
Investors should exercise caution and closely monitor Recursion's cash position and R&D pipeline progress. While revenue growth is positive, the escalating net losses suggest a need for significant future capital raises, which could dilute existing shareholders. Consider this a speculative long-term play on its platform, not a near-term value investment.
Financial Highlights
- debt To Equity
- Not Disclosed
- revenue
- $10.1M
- operating Margin
- Not Disclosed
- total Assets
- Not Disclosed
- total Debt
- Not Disclosed
- net Income
- -$105.3M
- eps
- Not Disclosed
- gross Margin
- Not Disclosed
- cash Position
- Not Disclosed
- revenue Growth
- +94.2%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| License and Service Agreements | $10.1M | +94.2% |
| Grants | Not Disclosed | Not Disclosed |
Key Numbers
- $10.1M — Q2 2025 Total Revenue (Increased 94.2% from $5.2M in Q2 2024)
- $105.3M — Q2 2025 Net Loss (Widened from $98.7M in Q2 2024)
- $19.5M — Six-Month 2025 Total Revenue (Increased 89.3% from $10.3M in 2024)
- $208.1M — Six-Month 2025 Net Loss (Widened from $192.5M in 2024)
- 94.2% — Q2 Revenue Growth (Year-over-year increase in total revenue)
Key Players & Entities
- RECURSION PHARMACEUTICALS, INC. (company) — filer of the 10-Q
- $10.1 million (dollar_amount) — total revenue for Q2 2025
- $5.2 million (dollar_amount) — total revenue for Q2 2024
- $19.5 million (dollar_amount) — total revenue for six months ended June 30, 2025
- $10.3 million (dollar_amount) — total revenue for six months ended June 30, 2024
- $105.3 million (dollar_amount) — net loss for Q2 2025
- $98.7 million (dollar_amount) — net loss for Q2 2024
- $208.1 million (dollar_amount) — net loss for six months ended June 30, 2025
- $192.5 million (dollar_amount) — net loss for six months ended June 30, 2024
- Bloomberg (company) — publisher of the analysis
FAQ
What were Recursion Pharmaceuticals' total revenues for Q2 2025?
Recursion Pharmaceuticals reported total revenues of $10.1 million for the three months ended June 30, 2025, a significant increase from $5.2 million in the same period of 2024.
How did Recursion Pharmaceuticals' net loss change in Q2 2025 compared to Q2 2024?
The net loss for Recursion Pharmaceuticals widened to $105.3 million for the three months ended June 30, 2025, compared to a net loss of $98.7 million for the same period in 2024.
What was the revenue growth percentage for Recursion Pharmaceuticals in Q2 2025?
Recursion Pharmaceuticals experienced a 94.2% year-over-year revenue growth for the three months ended June 30, 2025, with total revenue increasing from $5.2 million to $10.1 million.
What is the strategic outlook for Recursion Pharmaceuticals based on this 10-Q?
The strategic outlook for Recursion Pharmaceuticals appears to focus on advancing its drug discovery platform and leveraging license and service agreements, which are driving the observed revenue growth.
What are the primary risks for investors in Recursion Pharmaceuticals?
The primary risks for investors in Recursion Pharmaceuticals are the substantial and increasing net losses, which reached $105.3 million in Q2 2025, indicating a high cash burn rate and potential need for future financing.
How does Recursion Pharmaceuticals generate its revenue?
Recursion Pharmaceuticals generates its revenue primarily through license and service agreements, as indicated by the 'License and Service' revenue category in the filing.
What was Recursion Pharmaceuticals' net loss for the first six months of 2025?
For the six months ended June 30, 2025, Recursion Pharmaceuticals reported a net loss of $208.1 million, an increase from $192.5 million in the comparable period of 2024.
What impact do Recursion Pharmaceuticals' financial results have on its competitive position?
While Recursion Pharmaceuticals' revenue growth from collaborations demonstrates the value of its platform, the widening net losses could strain its financial resources and potentially impact its competitive edge against better-capitalized pharmaceutical companies.
Is Recursion Pharmaceuticals profitable?
No, Recursion Pharmaceuticals is not profitable; it reported a net loss of $105.3 million for Q2 2025 and a $208.1 million net loss for the first six months of 2025.
What is the significance of the increased revenue for Recursion Pharmaceuticals?
The increased revenue, up 94.2% to $10.1 million in Q2 2025, is significant as it indicates successful collaboration efforts and validation of Recursion Pharmaceuticals' drug discovery platform, providing crucial funding for its operations.
Risk Factors
- Substantial and Growing Net Losses [high — financial]: The company reported a net loss of $105.3 million for Q2 2025, an increase from $98.7 million in Q2 2024. The six-month net loss also widened to $208.1 million from $192.5 million in the prior year. This indicates a significant cash burn rate typical for a clinical-stage biotech company.
- Dependence on R&D Investment [high — operational]: Continued substantial investment in research and development is a key driver of the company's operations and future growth. However, this investment directly contributes to the widening net losses, highlighting the inherent risks in drug discovery.
- Reliance on Collaboration Funding [medium — financial]: Revenue growth is primarily driven by license and service agreements. This reliance on external collaborations means that the company's ability to fund operations is closely tied to the success and continuation of these partnerships.
Industry Context
The biopharmaceutical industry, particularly the drug discovery segment, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Recursion Pharmaceuticals leverage advanced technologies, such as AI and machine learning, to accelerate the identification and development of novel therapeutics. The competitive landscape is intense, with a constant need for innovation and strategic partnerships to fund operations and bring new treatments to market.
Regulatory Implications
As a clinical-stage biotech, Recursion Pharmaceuticals is subject to stringent regulatory oversight from bodies like the FDA. Successful navigation of clinical trials and regulatory approval processes is critical for drug commercialization. Any delays or failures in these processes can significantly impact the company's financial performance and market valuation.
What Investors Should Do
- Monitor R&D pipeline progress and clinical trial results.
- Evaluate the sustainability of the current cash burn rate.
- Assess the strength and diversification of collaboration agreements.
Glossary
- 10-Q
- A quarterly report filed by publicly traded companies with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on the company's financial performance. (This document is the source of the financial and operational data analyzed.)
- Clinical-stage biotech
- A biotechnology company that is in the process of developing drugs or therapies and is conducting or has completed clinical trials to test their safety and efficacy. (Describes Recursion Pharmaceuticals' current stage of development and the associated high-risk, high-reward profile.)
- Cash burn rate
- The rate at which a company is spending its available cash reserves, typically used to describe companies that are not yet profitable. (Key metric for understanding the financial sustainability of companies like Recursion Pharmaceuticals that are investing heavily in R&D.)
- License and Service Agreements
- Contracts where a company grants rights to its technology or services in exchange for fees or royalties. (A primary source of revenue for Recursion Pharmaceuticals, indicating the importance of strategic partnerships.)
Year-Over-Year Comparison
Recursion Pharmaceuticals has demonstrated impressive revenue growth, with Q2 2025 total revenue increasing by 94.2% year-over-year to $10.1 million. This growth is primarily attributed to its license and service agreements. However, this top-line expansion has been accompanied by a widening net loss, which increased from $98.7 million in Q2 2024 to $105.3 million in Q2 2025, reflecting continued heavy investment in research and development. No new significant risks were highlighted in the provided summary, but the existing risks related to high cash burn and reliance on collaborations remain prominent.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding RECURSION PHARMACEUTICALS, INC. (RXRX).